WuXi AppTec, beyond imagination

Nassim Nicholas Taleb reveals a profound truth in his business book “Antifragile”: true strength lies not only in surviving shocks but in becoming stronger from volatility, chaos, and pressure. WuXi AppTec is the best annotation of this concept in the pharmaceutical industry.

The global pharmaceutical market in 2025 resembles an unscripted improvisational performance: tariff policies hang overhead, regulatory undercurrents swirl, and the shadow of geopolitical tensions looms over the industry.

However, in such a noisy era, WuXi AppTec demonstrates astonishing composure, carving out a definite upward trajectory amid uncertainty.

This morning, WuXi AppTec’s A-shares surged by 6%, while Hong Kong shares rose more than 9%.

Navigating through the fog of cycles, WuXi AppTec’s 2025 financial report still maintains a rare beauty of economic growth.

01

Exciting Expectations for 2026

In 2025, WuXi AppTec once again delivered a record-breaking performance that surpassed expectations, achieving a remarkable lead:

● The momentum of growth will continue. The external environment in the past two years has not had a significant impact—annual overall revenue exceeded 45.46 billion yuan, a year-on-year increase of 15.8%;

● Efficiency and precision yield high-quality profits. Under the high pressure of global competition, WuXi AppTec still maintains enviable high-quality profits—net profit attributable to the parent company reached 19.15 billion yuan, soaring 102.6% year-on-year; adjusted non-IFRS net profit attributable to the parent company was 14.96 billion yuan, a year-on-year increase of 41.3%;

● Excellent cash flow is the best moat. Adjusted operating cash flow hit a historic high of 16.67 billion yuan, up 39.1% year-on-year—this is a perfect resonance of financial capability and strategic foresight.

The new year’s earnings pre-announcement sets an uplifting tone for WuXi AppTec’s 2026: the company expects overall revenue to reach 51.3-53 billion yuan, with continued operations revenue achieving a rapid year-on-year growth of 18-22%, and adjusted free cash flow to reach 10.5-11.5 billion yuan.

This means WuXi AppTec will maintain a high-speed growth momentum, officially entering a new era of “500 billion level.” After 2025, WuXi AppTec seems even stronger.

The business world is like tides; cycles are inevitable. But regardless of how the industry fluctuates, WuXi AppTec can always penetrate the fog, anchor its direction amid uncertainty, and be the first to provide predictable answers to the market, helping investors make the right decisions in a timely manner.

The market has always been full of beautiful promises; the courage to make promises is one thing, but the ability to fulfill them precisely is another. Over the past three years, WuXi AppTec has not only fulfilled all its performance expectations but has also consistently exceeded them. I believe this time will be no exception.

Against the backdrop of intensified industry fluctuations, WuXi AppTec can still clearly plan for the future and fulfill its promises precisely, showcasing the extraordinary management capabilities and strategic foresight of an outstanding enterprise.

02

Hearing the Tides from Afar

As 2026 begins, the global CXO industry is continuously active.

On February 25, Charles River Laboratories announced the sale of all its CDMO business to GI Partners, while also selling some European drug discovery service assets to industry competitor IQVIA. On March 6, Switzerland’s Lonza sold its capsule and health ingredient business (CHI) for 2.3 billion Swiss francs (approximately 3 billion USD), marking a return to the high-barrier, strong-synergy core business of “One Lonza.”

These two transactions may seem independent, but they point to the same consensus: against the backdrop of tightening geopolitical policies, increasing concentration of client pipelines, and rising regulatory compliance costs, the CXO model has transitioned from an expansion era to a new paradigm focused on collaboration and depth.

The industry suddenly realizes that WuXi AppTec’s “silent pivot” that began at the end of 2024 was not a response to changing circumstances but a foreshadowing of defining the future.

As early as December 2024, WuXi AppTec decisively divested its US and UK cell and gene therapy business WuXi ATU, leading peers like Charles River by over a year; in the following year of 2025, it exited US device testing and transferred clinical CRO, executing a series of strategic adjustments fluidly. It makes one wonder, just how far ahead does WuXi AppTec see?

In the balance of choices, WuXi AppTec opted to tilt its resources towards the high-certainty growth axis of end-to-end “small molecules + oligonucleotides + peptides + conjugated molecules.” While the industry changes were still unclear, WuXi AppTec had already completed strategic adjustments ahead of time, releasing the growth dividends brought by focus.

The 2025 financial report provides the most robust validation. Excluding asset disposal gains, WuXi AppTec’s core business still maintained high-quality profitability, exhibiting astonishing explosive power: revenue from continued operations reached 43.42 billion yuan, a year-on-year increase of 21.4%; adjusted non-IFRS net profit attributable to the parent company was 14.96 billion yuan, a year-on-year increase of 41.3%; both far exceeded the industry average.

In hindsight, WuXi AppTec’s series of “streamlining” actions was not a passive survival tactic but an active evolution based on profound insight.

In the uncertain field of pharmaceutical innovation, WuXi AppTec has found a definitive growth path: maintaining strategic clarity, grasping trends amid the tides of the times, and evolving into “certainty itself.”

03

Entering the BD Era

Despite the challenges posed by the external environment, large pharmaceutical companies (MNCs) and innovative biotechs have clarified their respective navigation amid the storm.

Authoritative forecasts indicate that over 300 billion USD in sales from blockbuster drugs will face the “patent cliff” before 2030. Faced with the potential for a massive revenue gap, MNCs have begun a global “shopping spree” for high-potential biotech molecules, coupled with a more cautious investment climate, giving rise to unprecedented enthusiasm for mergers and acquisitions and business development (BD). It is foreseeable that BD transactions will remain the main theme of industry innovation in the coming years.

As global biopharmaceutical BD transactions become increasingly rational and refined, a key variable previously often underestimated is rapidly rising to become a core dimension of due diligence for multinational pharmaceutical companies: the quality and reliability of the CXO partners that biotech companies collaborate with.

After all, the scientific rigor of the CXO, the maturity of the quality system, and the end-to-end collaborative capability directly impact the subsequent commercialization pace and regulatory risks for MNCs.

As biotech’s ultimate goal shifts from “creating molecules” to “realizing value,” the business value that WuXi AppTec can provide transcends service itself, embodying quality certainty that spans the entire cycle of R&D, testing, production, application, and commercialization.

In just 2025, WuXi AppTec underwent 741 quality audits and inspections from global clients, regulators, and third parties, with no significant findings. A quality system that withstands 741 trials unscathed is itself the most robust premium, making clients’ project pipelines more valuable in the capital market and more predictable in regulatory pathways.

For this reason, on the WuXi AppTec platform, the annual delivery volume of new small molecule compounds in the early research phase (R-end) can consistently maintain over 400,000. These are the sources of industry innovation and potential future “blockbusters.”

The underlying logic influencing biotech clients’ collaboration decisions is not only quality; delivery speed is also becoming a key trigger for premium negotiations and transaction closure.

In the past five years, the structural complexity index of new molecular entities (NMEs) has risen exponentially, traditional synthesis steps have lengthened, and yields have decreased progressively, with IND (Investigational New Drug) applications often delayed due to CMC bottlenecks. WuXi AppTec has demonstrated a hard-core research capability that simplifies complexity, often reducing reaction steps, significantly enhancing yields, and enabling early delivery.

In the ultimate game of new drug racing, this is not merely a time-saving measure—arriving months early at clinical trials or market launch means billions of dollars in market windows and first-mover barriers, and clients are willing to pay for this “step ahead” delivery capability.

In the BD era, WuXi AppTec’s value, combining quality and speed, stands out, earning dual trust from both biotech and MNCs. The data is the best proof; as of the end of December 2025, WuXi AppTec’s continued operations had an order backlog of up to 58 billion yuan, a year-on-year increase of 28.8%, sufficient to fully cover the performance guidance for 2026.

By understanding client needs, a winning strategy for sustainable growth has been locked in.

04

Firmly Investing in the Future

At a volatile turning point in the global pharmaceutical industry, steering a giant vessel with assets worth hundreds of billions, thousands of employees, and over 20 bases worldwide makes every correct decision extraordinarily challenging.

However, WuXi AppTec’s management team has displayed astonishing foresight and excellent management philosophy: seeing opportunities where others see challenges, acting decisively when others hesitate, and defining trends while others follow.

As an industry enabler, WuXi AppTec never hesitates to invest continuously for the future. It is expected that in 2026, its capital expenditures to accelerate global capacity deployment will reach 6.5-7.5 billion yuan. This figure is equivalent to the total assets of several dozen biotechs and is unique in the CXO field.

Such billions-level strategic investments are not spontaneous but a continuation of long-term forward-looking layouts. Just like the foresight in the layout of peptides and oligonucleotides has led to TIDES business now surpassing 10 billion yuan in revenue and leading capacity.

WuXi AppTec’s explosive performance in the face of adversity is merely the starting point for the new year.

In this transformative world, WuXi AppTec demonstrates that the most powerful moat is not scale or technology, but the ability to lead the future.